ARTICLE | Strategy
Three's company
How NCCN determines affordability in new cancer drug value framework
November 2, 2015 8:00 AM UTC
The National Comprehensive Cancer Network is the third physician group to launch a tool to assess the value of cancer drugs. Unlike the others, which compare drug benefits to a reported price, NCCN is asking panels of doctors to make a subjective judgment of affordability.
On Oct. 16, NCCN unveiled its Evidence Blocks tool, which scores treatment regimens on efficacy, safety, strength of the evidence, consistency of the evidence and affordability on a scale of 1-5...